VCYT VERACYTE, INC. Insider Trading

CEO Marc Stapley sells 138,051 VCYT shares at $50.12 via scheduled 10b5-1 plan; retains 440,494 shares post-sale

Marc Stapley, Chief Executive Officer of Veracyte, sold 138,051 shares (138.1K shares) for $6,919,585.49 on 2026-06-04 under a pre-arranged 10b5-1 trading plan adopted on 2025-11-24, reducing his direct holdings from 578,545 to 440,494 shares. The sale represents a 23.9% reduction of pre-transaction holdings, executed at $50.12, near the 52-week high of $50.71, as the stock has gained 51.5% over the past 30 days and 47.5% over 90 days. The transaction is scheduled under a trading plan, so it reflects a pre-determined execution rather than a discretionary timing decision. Notably, Stapley's prior five sales at Veracyte have shown mixed results: three earlier 2025 sales posted negative 30-day and 90-day returns, while two March 2026 sales saw near-term declines (-9.3% and -11.1% at 30 days) followed by strong 90-day recoveries (+34.4% and +31.8%). The company's fundamentals remain solid with annual revenue growth of +16.0%, net income of $28,707,000.00, and a market cap of $3,984,844,791.18 ($4.0B), though the P/E of 45.40 reflects premium valuation. The CEO retains a substantial equity stake of 440,494 non-derivative shares post-transaction.

VP CAO Jonathan Wygant sold 24,000 VCYT shares at $45.40 (worth $1.1M), reducing stake to 45.4K shares post-transaction

Jonathan Wygant, VP and Chief Accounting Officer, sold 24,000 shares of Veracyte at $45.40 on May 22, 2026, reducing his non-derivative holdings by 34.6% from 69.4K to 45.4K shares. The transaction value of $1.1M occurred near the stock's 52-week high of $50.71, and the sale is notable given the company's strong recent momentum (30-day return of +31.4%) and solid fundamentals including 16.0% annual revenue growth and a net income of $28.7M on $139.1M quarterly revenue. As a senior financial officer, Wygant's sale of this magnitude warrants investor attention to whether this reflects a scheduled vest-and-sell or discretionary rebalancing of his portfolio position, particularly in light of the elevated valuation environment reflected in the 40.45 P/E ratio.

CEO Marc Stapley sold 45,523 shares for $1,637,594.15 under pre-arranged 10b5-1 plan (adopted 2025-11-24)

Marc Stapley, CEO of Veracyte, sold 45,523 shares across 2 separate transactions on 2026-03-04, generating $1,637,594.15 at a blended average price of $35.97. This sale reduces his holdings from 403,077 shares to 357,554 shares, a decline of 11.3%. The transaction is part of a pre-arranged 10b5-1 trading plan adopted on 2025-11-24, meaning the sale was scheduled in advance rather than discretionary. As a routine scheduled disposition under a trading plan, this filing does not provide insight into current insider sentiment regarding the company's valuation or prospects.

CFO Rebecca Chambers sold 18,341 shares of VCYT for $662,869.24 under pre-arranged 10b5-1 plan adopted 2025-08-21.

Rebecca Chambers, Chief Financial Officer of Veracyte Inc., executed 2 separate sales totaling 18,341 shares on 2026-03-04 for $662,869.24 at a blended average price of $36.14. This sale reduced her holdings by 12.3% from 149,537 shares to 131,196 shares. The transaction was conducted under a pre-arranged 10b5-1 trading plan adopted on 2025-08-21, meaning it was scheduled rather than discretionary. As a CFO-level executive sale under a formal trading plan, this activity is within normal compliance-driven behavior and does not by itself indicate material concern about company prospects.

CFO Rebecca Chambers sold 13,278 VCYT shares for $621,955.21 across 2 transactions on 2025-12-04.

Rebecca Chambers, CFO of Veracyte Inc., executed 2 separate sales totaling 13,278 shares for $621,955.21 on 2025-12-04, reducing her holdings by 10.8% from 122.8K to 109.5K shares. The sales occurred at prices of $46.61 and $47.25 respectively, with a blended average of $46.84, near the current price of $47.41. Her cross-ticker track record shows 1 prior sell with a 90-day well-timed rate of 0.00%, and at VCYT specifically, her lone prior sale on 2024-11-12 generated +9.4% returns over 90 days (poorly timed, as the stock subsequently rose). The company trades at a P/E of 124.76 with annual revenue growth of +23.5%, and the stock is currently +31.3% over 30 days and +46.2% over 90 days, placing it 4.0% below its 52-week high. The timing and magnitude of this sale merit observation given the elevated valuation and recent sharp appreciation, though the absence of a pattern of well-timed sales at this ticker limits inference about forward-looking conviction.

Director Evan Jones sold 43,196 shares for $1,946,287.73 via scheduled 10b5-1 plan on 2025-11-05

Director Evan Jones executed 6 separate sales totaling 43,196 shares for $1,946,287.73 on 2025-11-05, reducing his holdings by 58.6% from 73,664 shares to 30,468 shares. The transaction occurred via a pre-arranged 10b5-1 trading plan adopted on 2024-12-09, meaning the sales were scheduled and non-discretionary. This is a material reduction in ownership percentage, though the automated nature of the plan removes any timing inference. Post-transaction holdings of 30,468 shares remain substantial, indicating Jones retains significant economic exposure to VCYT.

CEO Marc Stapley sold 52,697 shares for $1,756,855.23 under pre-arranged 10b5-1 plan

Marc Stapley, Chief Executive Officer of Veracyte Inc., executed 3 separate sales totaling 52,697 shares for $1,756,855.23 on 2025-03-04 under a 10b5-1 trading plan adopted on 2024-09-13. The sales occurred at prices ranging from $32.82 to $34.37, with a blended average of $33.34. Post-transaction, Stapley retains 268,035 shares, representing a 16.4% reduction in his shareholding. Because this transaction was part of a pre-arranged scheduled trading plan rather than a discretionary decision, it does not signal directional conviction about the stock's near-term prospects—the sale was determined months in advance and executed mechanically on the scheduled date.

SVP General Counsel Annie McGuire sold 18,699 shares of VCYT at $44.02; stock near 52-week high

SVP and General Counsel Annie McGuire sold 18,699 shares at $44.02, reducing her holdings by 20.4% from 91,568 to 72,869 shares and raising $823,178.60. The sale occurred with the stock trading at its 52-week high of $44.13—a notable threshold given the company's recent price momentum (up 54.5% over 90 days and 20.6% over 30 days). However, context matters: while the company has shown strong revenue growth of 21.8% annually and generated net income of $15,155,000.00 in the latest quarter, full-year earnings remain negative, indicating the company operates at an overall loss despite recent profitability in a single quarter. This sale by a General Counsel—a compliance officer and legal fiduciary—at a cyclical high warrants monitoring, though the modest reduction in absolute holdings preserves meaningful remaining ownership.

CFO Rebecca Chambers sold 15,275 shares of VCYT at $38.34; holds 124,501 shares post-sale

Rebecca Chambers, Chief Financial Officer of Veracyte Inc., sold 15,275 shares at $38.34 on 2024-11-12, reducing her holdings by 10.9% to 124,501 shares. The sale occurred near the company's 52-week high of $39.53, with the stock currently trading at $37.04. While the company showed strong recent performance (revenue of $115,860,000 in the latest quarter, annual revenue growth of 21.8%, and positive net income of $15,155,000 in that period), Veracyte reported negative full-year net income over its most recent complete fiscal year, indicating ongoing profitability challenges despite quarterly improvements. This represents a material open-market sale by a senior executive at a significant price level, warranting monitoring of company performance trends and any subsequent insider activity patterns.

Director Evan Jones sold 47,845 shares of VCYT across 8 transactions for $1,540,366.41 via pre-arranged 10b5-1 plan

Evan Jones, a director at Veracyte, executed 8 separate sales totaling 47,845 shares for $1,540,366.41 between August 12-13, 2024, reducing his holdings from 53,018 shares to 5,173 shares—a 90.2% reduction in position size. This substantial disposition was conducted under a pre-arranged 10b5-1 trading plan adopted on 2024-02-28, meaning the timing and structure of the sales were scheduled in advance rather than discretionary responses to current market conditions. The blended average sale price of $32.19 reflects the actual transaction prices across the eight tranches. Investors should note that the magnitude and breadth of this near-complete liquidation by a director represents a material change in insider holdings, though the scheduled nature of the plan indicates this outcome was predetermined months prior.